WALTHAM, Mass. - eTradeWire -- The U.S. Food and Drug Administration (FDA) has cleared Nova Primary as a blood glucose reference analyzer. Nova Primary fills the need for a new glucose reference analyzer to replace the discontinued YSI STAT PLUS 2300 Glucose and L-Lactate analyzer (YSI, Inc., Yellow Springs, OH).

Manufacturers of blood glucose measuring devices and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, YSI, Inc. no longer supports the analyzer, and its discontinuation has left a critical industry void. The Nova Primary analyzer fills that need. With today's FDA clearance, Nova Primary is now available in the U.S. and worldwide. According to Matthew McRae, Nova Sales Product Line Manager, "We at Nova Biomedical are pleased to offer the Nova Primary, an accurate, easy-to-use and modernized blood glucose reference analyzer for glucose device manufacturers and clinical diabetes researchers to replace the discontinued YSI Stat Plus glucose analyzer."

More on eTradeWire News

• The Swig Company Announces Long-Term Lease with Silicon Valley Community Foundation in Mountain View
• BayView Entertainment and Paris Films Enter First Look Agreement
• Tarps Now® Releases Guide to Best Tarps to Buy
• IISE announces leadership election results
• JD Merit & Co. Advises Amtech Systems, Inc. in its Acquisition of Entrepix, Inc

Like the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 20-900 mg/dL. It uses a small, 25 microliter venous whole blood or plasma sample which is internally diluted as in the YSI. Results are available in approximately 2 minutes. Nova Primary's large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and number of samples remaining, eliminating the need for separate reagent bottles and daily monitoring of their levels. In clinical laboratory studies using venous whole blood and plasma, the Nova Primary demonstrated excellent correlation to the YSI 2300 and is traceable to NIST glucose standards. The Nova Primary uses a comma delimited (.csv) format data output that can be downloaded via the integral USB data port. The analyzer measures 17 in x 11 in x 18 in (44 cm x 28 cm x 46 cm).

More on eTradeWire News

• 2023 Book Award Winners Announced
• Brian Lottermann Promoted to Agent at Universal Attractions Agency
• Custom Engraved Firefighter Coins Make A Great Retirement Gift
• Tyler Clark Joins Global Learning Charter Public School as a Grade 5 ELA Teacher
• KITROBOT Intelligent System Corp. Introduces an AI-Powered Disinfecting Robot For Automated Cleaning

About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova employs over 1,400 people worldwide and has wholly owned subsidiaries located in Benelux, Brazil, Canada, France, Germany, Great Britain, Italy, Japan, Spain, and Switzerland.